132431-09-5

Basic information

• Product Name: (Cbz-4-aminomethyl)piperidine, min. 95 %
• Synonyms: (Cbz-4-aminomethyl)piperidine, min. 95 %;(CBZ-4-AMINOMETHYL)PIPERIDINE;benzyl piperidin-4-ylmethylcarbamate hydrochloride;benzyl piperidin-4-ylMethylcarbaMate;benzyl N-(piperidin-4-ylMethyl)carbaMate;CarbaMic acid, (4-piperidinylMethyl)-, phenylMethyl ester;CarbaMic acid,N-(4-piperidinylMethyl)-, phenylMethyl ester;Phenylmethyl [(4-piperidinyl)methyl]carbamate
• CAS NO: 132431-09-5
• Molecular Formula: C₁₄H₂₀N₂O₂
• Molecular Weight: 248.32
• Mol File: 132431-09-5.mol

Chemical Properties

• Boiling Point: 409.245 °C at 760 mmHg
• Flash Point: 201.304 °C
• Appearance: /
• Density: 1.082 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.524
• PKA: 12.51±0.46(Predicted)
• CAS DataBase Reference: (Cbz-4-aminomethyl)piperidine, min. 95 %(CAS DataBase Reference)
• NIST Chemistry Reference: (Cbz-4-aminomethyl)piperidine, min. 95 %(132431-09-5)
• EPA Substance Registry System: (Cbz-4-aminomethyl)piperidine, min. 95 %(132431-09-5)

Safety Data

• Hazardous Substances Data: 132431-09-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(Cbz-4-aminomethyl)piperidine, min. 95% is used as a key intermediate in the synthesis of various drugs for pharmaceutical research. Its presence in the compound allows for the creation of new drug candidates with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic chemistry, (Cbz-4-aminomethyl)piperidine, min. 95% is used as a building block for the synthesis of complex organic molecules. The carbobenzyloxy protective group and the functionalized piperidine ring provide a versatile platform for further chemical reactions and modifications.
Used in Drug Production:
(Cbz-4-aminomethyl)piperidine, min. 95% is used as a starting material in the production of various drugs. Its high purity and structural features make it an ideal candidate for the development of new pharmaceuticals with improved efficacy and safety profiles.

InChI:InChI=1/C14H20N2O2/c17-14(16-10-12-6-8-15-9-7-12)18-11-13-4-2-1-3-5-13/h1-5,12,15H,6-11H2,(H,16,17)

Upstream product

• 155456-33-0 4-(Benzyloxycarbonylamino-methyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 22129-07-3 N-benzyloxycarbonylimidazole 
• 7144-05-0 4-Aminomethylpiperidine 
• 132431-14-2 4-(Benzyloxycarbonylamino-methyl)-piperidine-1-carboxylic acid benzyl ester 

Downstream Products

• 170353-28-3 (1-(pyridin-2-yl)piperidin-4-yl)methanamine 
• 302341-46-4 benzyl ((1-(pyridin-2-yl)piperidin-4-yl)methyl)carbamate 
• 1342815-16-0 N-[[1-{3-(1,2,3-triazol-1-yl)propyl}piperidin-4-yl]methyl]-4-amino-5-chloro-2-methoxybenzamide 
• 1615249-70-1 C₂₆H₃₀BrN₃O₄ 
• 941692-40-6 phenylmethyl ({1-[(3R)-tetrahydro-3-furanylmethyl]-4-piperidinyl}methyl)carbamate 
• 941692-37-1 phenylmethyl ({1-[(3S)-tetrahydro-3-furanylmethyl]-4-piperidinyl}methyl)carbamate 
• 172348-56-0 benzyl 4-(((tert-butoxycarbonyl)amino)methyl)piperidine-1-carboxylate 

Relevant articles and documents

4-AMINO-BENZAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL, NEUROLOGICAL AND CARDIOVASCULAR DISORDERS

The present invention relates to novel benzamide derivatives of formula (I) having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of diseases treatable by 5-HT4 agonism.

NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

Novel tricyclic compounds of formula (1.0) or a pharmaceutically acceptable salt or solvate thereof, wherein: one of a, b, c, and d represents N or NR, wherein R is O-, -CH3 or -(CH2)nCO2H wherein n is 1 to 3, and the remaining a, b, c and d groups represent CR or CR; or each of a, b, c and d is independently selected from CR or CR; each R and each R is independently selected from H, halo, -CR3, -OR, -COR, -SR, -S(O)tR (wherein t is 0, 1 or 2), -SCN, -N(R)2, -NRR, -NO2, -OC(O)R, -CO2R, -OCO2R, -CN, -NHC(O)R, -NHSO2R, -CONHR, -CONHCH2CH2OH, -NRCOOR, -SRC(O)OR, -SRN(R); n is 0 (zero), 1, 2, 3, 4, 5 or 6; T is -CO-; -SO-; -SO2-; or -CRR-; Z represents alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -OR, -SR, -CRR, -NRR, formulae (i), (ii), (iii), (iv), (v) and (vi). Pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel tricyclic compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human.

Boron trifluoride promoted cleavage of benzyl carbamates

A new efficient method for the cleavage of benzyl carbamates (CBZ protective groups) is described that involves a hard acid (BF3·OEt2) - soft nucleophile (EtSH) system. Unlike other available methods, this combination avoids the reduction of olefins, acetylenes, imines, halides and nitro groups, or the possibility of carboxylic ester hydrolysis.